![]() The ROS1ders Announces Recipients of Inaugural ROS1+ Cancer Innovation AwardsBy: The ROS1ders, Inc SACRAMENTO, Calif. - Oct. 23, 2023 - PRLog -- The ROS1ders, a global group of patients and caregivers living with ROS1+ cancer, announced the inaugural recipients of The ROS1+ Cancer Innovation Award. Funds were raised through individual contributions by patients and supporters. Each award carries a one-year $75,000 seed grant to fund high-risk, high-reward research projects in ROS1+ cancer.
The recipients are:
About The ROS1ders The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Please visit theros1ders.org to learn more. About ROS1+ Cancer ● ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer. The incidence is thought to be similar in other types of cancer. ● Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer, but few other cancers, yet. ● Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies). ● Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+ NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood. End
|